Regeneron Statistics, Revenue Totals, Facts & News (2022)
Last Updated on: March 31st, 2022
Here are a few of the most interesting Regeneron statistics and facts I was able to dig up including revenue totals and employee counts. As always, be sure to check back in the future as I will be updating this post as new and updated stats become available.
Regeneron Facts
- Regeneron Website: Official Website
- Year Regeneron was Founded: 1988
- Regeneron Headquarters: Eastview, NY
- Regeneron Founder(s): Leonard Schleifer, Eric Manvers Shooter
- Current Regeneron Chief Executive: Leonard Schleifer
What is Regeneron?
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases. (source)
Regeneron Revenue Totals
Regeneron annual revenue:
- 2021: $16.071 billion
- 2020: $8.497 billion
- 2019: $7.863 billion
- 2018: $6.710 billion
- 2017: $5.872 billion
- 2016: $4.860 billion
- 2015: $4.104 billion
- 2014: $2.820 billion
Regeneron annual net income:
- 2021: $9.075 billion
- 2020: $3.513 billion
- 2019: $2.115 billion
- 2018: $2.444 billion
- 2017: $1.198 billion
- 2016: $895 million
- 2015: $636 million
Recent Regeneron News
- Regeneron reports ‘successful’ year with $16 billion revenue in 2021, 04/28/2022
- Sanofi, Regeneron build their case for yet another approval for immunology star Dupixent, 02/28/2022
Related posts:
Please note that some of these numbers are easier to find than others. A few of these Regeneron statistics come from their own reports, but some are based on news reports and not official company tallies. No information contained on DMR should be relied upon to make investment decisions. Basically, this is the best I can find and I don’t guarantee anything to be 100%.
Related Categories:
Related Tags: